🟢 87/100

This product is generally safe

  • Niacin: 100mg is 2.9× the Tolerable Upper Intake Level (35mg)
  • 67% of ingredients have research evidence
C Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Safety Alerts

⚠️ Niacin: 100mg is 2.9× the Tolerable Upper Intake Level (35mg)

Label Data

1 Capsule(s) Serving Size
Other Combinations Product Type
67% Evidence Coverage

Supplement Facts — Evidence Check

100 mg (500% DV)
⚠️ Exceeds Tolerable Upper Intake Level by 2.9× (UL: 35 mg) 📚 193 studies (Tier A: 5, B: 63)
RDA 14mg This product: 100mg UL 35mg
50 mg (500% DV)
📊 10.0× RDA — above typical dose 📚 1 studies — no high-quality reviews
RDA 5mg This product: 50mg
50 mcg (42% DV)
✅ 1.4× RDA — within safe limits 📚 197 studies (Tier A: 1, B: 55)
RDA 0.035mg This product: 0.05mg

Other Ingredients

Cellulose Gelatin Vegetable Stearate

Label Claims — Verification

All Other
All Other (97% of products) Structure/Function (86% of products) Nutrient (36% of products)

Target Groups

Adult (18 - 50 Years) Dairy Free Sugar Free

Product Information

📋 Directions for Use

Suggested Usage: As a dietary supplement, adults take 1 capsule daily or as directed by healthcare professional.

⚠️ Warnings & Precautions

KEEP OUT OF REACH OF CHILDREN.

Tamper resistant package, do not use if outer seal is missing.

🧪 Formulation Notes

This product contains NO yeast, wheat gluten, soy protein, milk/dairy, corn, sodium, sugar, starch, artificial coloring, preservatives or flavoring.

Additional Information

Formula #7061

For optimal storage conditions, store in a cool, dry place. (59°-77°F/15°-25°C) (35-65% relative humidity)

Product Details

UPC / SKU 3 10539 00693 1
DSLD Entry Date 2012-04-26
Product Type Other Combinations
Form Capsule
DSLD ID 8108
Data Updated 2026-04-11

Research Evidence

241 Research Sources
55 Avg Quality Score
113 Meta Analysis
75 Systematic Review
32 Rct
11 Clinical Trial
3 Other
3 Regulatory Source
1 Cochrane Review
1 Narrative Review
1 Openfda Safety
A Niacin for primary and secondary prevention of cardiovascular events
Meta Analysis The Cochrane database of systematic reviews 2017
A Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases
Meta Analysis BMJ (Clinical research ed.) 2013
A Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients
Meta Analysis BMJ (Clinical research ed.) 2014
A A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk
Meta Analysis Nature medicine 2024
A Meta-analysis and imputation refines the association of 15q25 with smoking quantity
Meta Analysis Nature genetics 2010
A Genome-wide meta-analyses identify multiple loci associated with smoking behavior
Meta Analysis Nature genetics 2010
A Antidepressants for smoking cessation
Meta Analysis The Cochrane database of systematic reviews 2014
A Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne
Meta Analysis The Cochrane database of systematic reviews 2020
B Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis
Meta Analysis JAMA network open 2019
B Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis
Meta Analysis JAMA 2016
View all evidence for Niacin →

Compare Similar Products

View all Niacin products →